NSE: ALKEM · 23 October 2026
- Alkem Laboratories Ltd. shares fell 1.33% on October 23, 2026, closing at ₹4,947.00 after trading between an intraday high of ₹5,019.50 and a low of ₹4,877.00. The stock opened lower at ₹4,976.50 following a gap down of 0.74% from its previous close of ₹5,013.50.
- Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.
- Trading volume was 0.38 times the 20-day average daily volume.
Why is Alkem Laboratories share price falling on 23 October 2026?
Alkem Laboratories Ltd. shares fell 1.33% on October 23, 2026, closing at ₹4,947.00 after trading between an intraday high of ₹5,019.50 and a low of ₹4,877.00. The stock opened lower at ₹4,976.50 following a gap down of 0.74% from its previous close of ₹5,013.50.
The broader pharmaceutical sector also faced selling pressure, with the Nifty Pharma benchmark declining by 1.04% and the broader Nifty slipping 0.39%. Alkem's move aligns with a broader retracement in healthcare stocks, compounded by its own recent downward momentum that shows a 3.39% decline over the past 5 trading days and an 8.68% drop over the past 20 trading days.
Company disclosures from October 21, 2026, revealed that Alkem's audit committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP regarding an alleged misappropriation of funds by a former employee involving procurement transactions. While this governance update provides notable background context regarding ongoing internal investigations, no direct causality with today's intraday price action has been formally established.
54,982 shares traded by 23 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.44 lakh shares (0.38 times). The five-day average daily volume was 1.29 lakh shares. Separately, the NSE report for 23 October 2026 showed 28,025 shares delivered, representing 50.97% of that day’s traded volume. The same report recorded 8,341 trades.
Alkem's 1.33% decline occurred alongside broader weakness in the Nifty Pharma sector and below-average trading volume. While the recent announcement of a forensic audit regarding a former employee's procurement transactions provides negative sentiment background, the move primarily reflects general sector pressure and continued short-term downward momentum.
Latest Company Developments
Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.
Independent forensic reviews highlight governance scrutiny and operational oversight over employee transactions, which can influence investor sentiment regarding internal controls.
The company announced the appointment of Mr. Laxmikant Tiwari as Senior Management Personnel for pharmaceutical operations and Mr. Nilesh Vartak for supply chain leadership, both effective October 12, 2026. Both executives bring over two decades of industry experience.
Leadership additions in operations and supply chain aim to strengthen execution capabilities across manufacturing and distribution channels.
Alkem reported that Chief Financial Officer Mr. Nitin Agrawal resigned on July 30, 2026, to pursue new professional opportunities, formally ceasing to hold his senior management position effective September 30, 2026.
Transitions in key financial leadership roles require close monitoring for continuity in financial reporting and strategic execution.
a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.".
Appointment of Mr Nilesh Vartak as Senior Management Personnel of the company effective. October 12, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.
The filing reported 29 MF/UTI holders.
Research & Brokerage Views
Maintained a neutral stance with a target price of ₹5,770 following Q1 earnings results that featured a profit beat, balancing operational growth against valuation considerations.
Historical Bulk / Block Deals
What to Watch Next
- Developments and findings from the ongoing forensic audit conducted by Grant Thornton Bharat LLP.
- Execution and delivery volumes relative to the 20-day average volume of 38% observed today.
- Stability and transition progress following recent senior management and CFO changes.
- Domestic market performance across acute and chronic pharmaceutical therapeutic segments.
Other Dated Coverage
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.03% | 22 October 2026 — 22 October 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026 — 14 October 2026
- Alkem Laboratories in Focus After Senior Management Appointments | 13 October 2026 — 13 October 2026
More Alkem Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Alkem Laboratories company news?
Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.
How strong was Alkem Laboratories’s trading volume?
54,982 shares traded, 0.38 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.